title: Glucosylceramide synthase, a factor in modulating drug resistance, is overexpressed in metastatic breast carcinoma.
abstract: Drug resistance causes treatment failure in approximately 50% of breast cancer patients with chemotherapy. Overexpression of glucosylceramide synthase (GCS) confers drug resistance in cancer cells, and suppression of GCS sensitizes cancers to chemotherapy in preclinical studies. Thus, GCS becomes a potential target to reverse drug resistance; however, little is known about GCS expression levels in normal tissues and whether GCS overexpression is associated with metastatic cancers. Herewith, we report our studies in GCS expression levels and breast cancer from patients. GCS levels were analyzed using cancer profiling arrays, breast cancer histo-arrays and quantitative RT-PCR in tumor tissues. We found that breast (18 exp. index) and other hormone-dependent organs (testis, cervix, ovary, prostate) displayed the lowest levels of GCS mRNA, whereas liver (52 exp. index) and other organs (kidney, bladder, stomach) displayed the highest levels of GCS. GCS mRNA levels were significantly elevated in tumors of breast, cervix, rectum and small intestine, as compared to each paired normal tissue. In mammary tissue, GCS overexpression was detected in breast cancers with metastasis, but not in benign fibroadenoma or primary tumors. GCS overexpression was coincident with HER2 expression (γ2=0.84) in ER-negative breast adenocarcinoma. In tumor specimens, GCS mRNA was elevated by 4-fold and significantly associated with stage III (5/7), lymph node-positive (7/8) and estrogen receptor-positive breast cancers (7/9). GCS expression was significantly and selectively elevated in breast cancer, in particular in metastatic disease. GCS overexpression was highly associated with ER-positive and HER2-positive breast cancer with metastasis. Although a small study, these data suggest that GCS may be a prognostic indicator and potential target for the treatment of chemotherapy-refractory breast cancer.
authors: Department of Basic Pharmaceutical Sciences, University of Louisiana at Monroe, 700 University Avenue, Monroe, LA 71209, USA. yliu@ulm.edu
authors: Yong-Yu
authors: YY
authors: Liu
authors: Gauri A
authors: GA
authors: Patwardhan
authors: Ping
authors: P
authors: Xie
authors: Xin
authors: X
authors: Gu
authors: Armando E
authors: AE
authors: Giuliano
authors: Myles C
authors: MC
authors: Cabot
references: Cancer Res. 1997 May 15;57(10):1882-8
references: 9157980
references: Cancer Biol Ther. 2009 Jun;8(12):1117-21
references: 19502811
references: Mol Cancer Ther. 2004 May;3(5):633-9
references: 15141021
references: Leuk Res. 2008 Mar;32(3):475-80
references: 17709137
references: Clin Cancer Res. 2005 Aug 15;11(16):5730-9
references: 16115910
references: Anticancer Res. 1998 Jan-Feb;18(1B):475-80
references: 9568165
references: FASEB J. 2001 Mar;15(3):719-30
references: 11259390
references: Urol Oncol. 2012 Jul-Aug;30(4):444-9
references: 20843709
references: J Cell Biol. 1992 Apr;117(2):259-67
references: 1532799
references: J Natl Cancer Inst. 2001 Mar 7;93(5):347-57
references: 11238696
references: J Biol Chem. 1994 Feb 4;269(5):3125-8
references: 8106344
references: J Biol Chem. 1996 Aug 9;271(32):19530-6
references: 8702646
references: Drug Resist Updat. 2001 Dec;4(6):368-77
references: 12030784
references: Oncogene. 2003 Sep 1;22(37):5897-906
references: 12947396
references: Cancer Res. 2011 Mar 15;71(6):2276-85
references: 21278235
references: Trends Cell Biol. 2001 Nov;11(11):S22-6
references: 11684438
references: Cancer Metastasis Rev. 1994 Jun;13(2):223-33
references: 7923552
references: Lancet Oncol. 2010 Apr;11(4):358-65
references: 20189874
references: Cancer Lett. 2004 Apr 8;206(2):169-80
references: 15013522
references: Expert Rev Anticancer Ther. 2001 Dec;1(4):585-94
references: 12113091
references: FASEB J. 2008 Jul;22(7):2541-51
references: 18245173
references: Nat Rev Cancer. 2002 Jan;2(1):48-58
references: 11902585
references: Nat Rev Mol Cell Biol. 2008 Feb;9(2):139-50
references: 18216770
references: J Cancer Res Clin Oncol. 2009 Jan;135(1):81-90
references: 18560890
references: J Biol Chem. 1999 Jan 8;274(2):1140-6
references: 9873062
references: Exp Cell Res. 1999 Nov 1;252(2):464-70
references: 10527636
references: Glycoconj J. 2009 Jul;26(5):547-58
references: 19219548
references: Adv Exp Med Biol. 2007;608:1-22
references: 17993229
references: Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19087-92
references: 16365318
references: PLoS One. 2009 Sep 09;4(9):e6938
references: 19742320
references: BJU Int. 2008 Aug;102(4):510-5
references: 18476970
references: Nat Rev Cancer. 2004 Aug;4(8):604-16
references: 15286740
references: Clin Cancer Res. 2003 Jan;9(1):415-23
references: 12538495
references: Biochem Pharmacol. 2010 Jul 1;80(1):72-9
references: 20298675
references: Curr Opin Pharmacol. 2006 Aug;6(4):350-4
references: 16690355
references: J Biol Chem. 2001 Jul 6;276(27):24901-10
references: 11335714
references: Mol Cancer. 2010 Jun 11;9:145
references: 20540746
references: Curr Drug Targets. 2004 May;5(4):375-82
references: 15134220
references: Trends Biochem Sci. 1999 Jun;24(6):224-5; author reply 227
references: 10366847
references: Clin Ther. 2009 Aug;31(8):1619-40
references: 19808124
references: Cancer Cell. 2007 Jun;11(6):473-5
references: 17560328